PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 5, 2026British Journal of Dermatology0 citationsOpen Access

Efficacy and safety of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma in Japan: Results of the Japan Clinical Oncology Group single-arm confirmatory trial (JCOG1605)

View Full Paper
KOKohei OashiDODai OgataMYMasayuki Yokoyama

Key Points

  • This research aims to evaluate pazopanib's efficacy and safety in patients with angiosarcoma previously treated with paclitaxel.
  • Single-arm confirmatory trial design
  • Population: patients with primary cutaneous angiosarcoma
  • Treatment: pazopanib administration
  • Endpoints: progression-free survival, response rate, overall survival
  • Progression-free survival did not meet the threshold
  • Response rate was better than expected
  • Overall survival improved
  • No significant safety issues reported

Abstract

The primary endpoint progression-free survival did not meet the predefined threshold. However, the response rate and overall survival were better than expected, and there were no safety issues. Therefore, pazopanib may be a treatment option for patients with paclitaxel-pretreated primary cutaneous angiosarcoma. (231/350 words).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Oashi et al. (2026) studied this question.

synapsesocial.com/papers/69a91e65d6127c7a504c2502https://doi.org/10.1093/bjd/ljag071
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face1999 · 388 citations
  2. 2Angiosarcoma of the scalp successfully treated with pazopanib2013 · 32 citations
  3. 3OER‐073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma2022 · 31 citations
  4. 4Paclitaxel Given Once Per Week With or Without Bevacizumab in Patients With Advanced Angiosarcoma: A Randomized Phase II Trial2015 · 193 citations
  5. 5Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas2011 · 160 citations